Add-on Venetoclax before stem cell transplant for AML/MDS
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests adding venetoclax to the usual chemotherapy (fludarabine and melphalan) given before a stem cell transplant for older adults with AML or MDS. The goal is to see if the combination helps prevent the disease from coming back after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 51 years old or older.
- You must have acute myeloid leukemia (AML) in remission, a higher-risk myelodysplastic syndrome (MDS), or MDS/MPN overlap.
- You must have a donor (related or unrelated) and be scheduled for a stem cell transplant.
- You must be in good enough health to handle the strong chemotherapy preparation (performance score of 70 or higher).
- You cannot have severe heart, lung, liver, or kidney problems that make the conditioning regimen unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the combination of venetoclax (a targeted pill) and azacitidine (a chemotherapy-like drug) as consolidation therapy after initial treatment in adults with high-risk acute myeloid leukemia (AML) who have achieved remission and are planning a stem cell transplant. The goal is to see if this combination helps prevent relapse before transplant.
This trial tests adding venetoclax to a standard “conditioning” chemotherapy plan before an allogeneic stem cell transplant (using a donor) for certain bone marrow cancers. It aims to improve how well the transplant works and how safe this combination is for people with MDS, CMML, or sAML.
This trial tests whether adding a drug called venetoclax to a standard transplant preparation regimen (called treosulfan-based reduced intensity conditioning) can improve the success of a stem cell transplant for patients with certain blood cancers like AML, MDS/AML, or high-risk MDS. The goal is to see if this combination makes the transplant safer and more effective.
This trial tests a combination of two drugs (venetoclax and azacitidine) given before a stem cell transplant to see if it improves outcomes for people with a certain type of myelodysplastic syndromes (MDS) that is higher risk. If you have higher-risk MDS and are planning a stem cell transplant, this may be an option.
This trial tests whether adding venetoclax (a pill that targets cancer cells) to the standard chemotherapy regimen before a stem cell transplant improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It is for patients aged 12–60 whose cancer has specific high-risk features and who have a matched donor.
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
Hear when a new Venentoclax trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.